

HuGemm™ and HuCell™

Humanized drug target models for immunotherapy evaluation


Discover the benefits that unique humanized target models featuring functional immune systems bring to immunotherapy drug development programs.

HuGemm and **HuCell** models allow the rapid evaluation of human-specific biological therapies *in vivo*, with:

- **HuGemm** mouse models with stable humanized drug target expression, including PD-1, PD-L1, and CTLA-4
- **HuCell** syngeneic tumor cells with stable humanized ligand expression, e.g. PD-L1
- Key checkpoint target platforms developed, including double knock-in models for combination ICI assessment, with many more under development

Choose **HuGemm** and **HuCell** humanized drug target models to:

- Interrogate the effectiveness of human-specific checkpoint inhibitors alone, or in combination with therapeutics potentiating the tumor immune microenvironment
- Evaluate your immunotherapies within a competent murine immune system featuring relevant human-specific targets
- Combine **HuGemm** and **HuCell** models for a fully humanized receptor-ligand complex
- Assess target engagement and pharmacodynamics of your immuno-oncology agents



Get in touch



Sales

US: +1 858 622 2900
UK: +44 870 166 6234

busdev@crownbio.com
www.crownbio.com



Science

consultation@crownbio.com

